154 related articles for article (PubMed ID: 16110609)
1. Topoisomerase II inhibitors.
Martincic D; Hande KR
Cancer Chemother Biol Response Modif; 2005; 22():101-21. PubMed ID: 16110609
[No Abstract] [Full Text] [Related]
2. Topoisomerase II inhibitors.
Hande KR
Cancer Chemother Biol Response Modif; 2003; 21():103-25. PubMed ID: 15338742
[No Abstract] [Full Text] [Related]
3. Etoposide: four decades of development of a topoisomerase II inhibitor.
Hande KR
Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of topoisomerase-interactive drugs.
Muggia FM; Burris HA
Adv Pharmacol; 1994; 29B():1-31. PubMed ID: 8996599
[No Abstract] [Full Text] [Related]
5. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
6. Etoposide sensitivity of radioresistant human glioma cell lines.
Beauchesne P; Bertrand S; N'guyen MJ; Christianson T; Dore JF; Mornex F; Bonner JA
Cancer Chemother Pharmacol; 1998; 41(2):93-7. PubMed ID: 9443620
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
8. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
[No Abstract] [Full Text] [Related]
9. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity.
Prabhu NS; Somasundaram K; Tian H; Enders GH; Satyamoorthy K; Herlyn M; El-Deiry WS
Int J Oncol; 1999 Aug; 15(2):209-16. PubMed ID: 10402229
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.
Jensen PB; Sehested M
Biochem Pharmacol; 1997 Oct; 54(7):755-9. PubMed ID: 9353129
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of anticancer drugs targeted to topoisomerase II.
Hande KR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):173-84. PubMed ID: 9748560
[TBL] [Abstract][Full Text] [Related]
12. Role of topoisomerase I inhibitors in small-cell lung cancer.
Fukuoka M
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related acute promyelocytic leukemia following etoposide-based chemotherapy in non-seminomatous germ cell tumor.
Kumar TN; ; Gandhi LV; Raghunadharao D; Sadashivudu G
J Postgrad Med; 2014; 60(1):84-5. PubMed ID: 24625948
[TBL] [Abstract][Full Text] [Related]
14. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
15. Culprit and victim -- DNA topoisomerase II.
Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P
Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
17. Catalytic topoisomerase II inhibitors in cancer therapy.
Larsen AK; Escargueil AE; Skladanowski A
Pharmacol Ther; 2003 Aug; 99(2):167-81. PubMed ID: 12888111
[TBL] [Abstract][Full Text] [Related]
18. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
19. New drug therapy for squamous carcinoma of the head and neck.
Murphy BA
Curr Opin Oncol; 1996 May; 8(3):221-6. PubMed ID: 8794150
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase-I inhibitors in gynecologic tumors.
Haluska P; Rubin E; Verschraegen CF
Hematol Oncol Clin North Am; 1999 Feb; 13(1):43-61, vii-viii. PubMed ID: 10080069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
